regulatory record
The 503A Bulks List and the July 2026 advisory committee vote
On 23 and 24 July 2026 an FDA advisory committee voted on seven peptides. The votes were widely reported as a clearance. They were not one. This page reads the meeting against FDA's own documents and separates what happened from what changed.
The short version
A committee that advises FDA recommended six of seven peptides for a list that would let compounding pharmacies use them. FDA staff had proposed the opposite on every one. The recommendation is advisory, it binds nobody, and it changed no law: the same substances are in the same legal position today as they were on 22 July.
This page exists because the gap between those two sentences is where the category is currently getting it wrong. Headlines published in the days after the meeting described the outcome as FDA clearing peptides for compounding. FDA cleared nothing. A committee gave advice, and the agency has not acted on it.
What the 503A Bulks List is
Section 503A of the Federal Food, Drug, and Cosmetic Act sets out when a drug compounded by a licensed pharmacist or physician is exempt from three requirements that otherwise apply: new drug approval, labelling with adequate directions for use, and current good manufacturing practice.
One condition of that exemption concerns the bulk substance the compounder starts from. It must meet a United States Pharmacopeia or National Formulary monograph if one exists. If no monograph exists, it must be a component of an approved drug. If neither is true, it has to appear on a list FDA develops by regulation. That list is the 503A Bulks List, and it is the only route onto which any of these seven peptides could travel.
FDA set the evaluation criteria in a final rule published on 19 February 2019 at 84 FR 4696. There are four: the physical and chemical characterization of the substance, safety issues raised by its use in compounded products, evidence of effectiveness or lack of effectiveness, and historical use in compounding. The agency applies them as a balancing test, substance by substance, rather than as a checklist.
FDA proposed against all fourteen
Seven peptides went to the committee, each as two separate substances: a free base and an acetate. That makes fourteen voting questions rather than seven.
FDA's briefing document for the meeting lists its own position on every one of the fourteen, in the section headed Points to Consider. Each entry reads the same way: FDA is proposing that the substance not be included on the 503A Bulks List. There is no exception in the document. The agency went into the meeting recommending against BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and semax, in both forms of each.
The committee's own presentations, delivered by FDA staff on both days, end each substance with the same formula: a balancing of the criteria weighs against the substance being placed on the list. Behind that formula is a consistent set of findings, and the most common one is not a safety finding. It is that the substances are not well characterized: FDA states across all seven that it could not establish what the material being nominated actually is, in physical and chemical terms.
What the committee did, and the figure this site is not printing
The committee voted against FDA's proposal on six of the seven peptides. Contemporaneous accounts published by Holland & Knight, Mintz, McDermott Will & Emery, Buchanan Ingersoll & Rooney and the American Journal of Managed Care agree on the outcome: BPC-157, KPV, TB-500, MOTS-c, semax and epitalon were recommended for inclusion, and emideltide, also called delta sleep-inducing peptide, was not.
FDA has published no vote record. The documents the agency has posted for this meeting are the briefing document, the agenda, the draft roster, the webcast notice and the two introductory slide decks. All of them were prepared before the meeting. None of them contains a tally.
Vote counts are circulating, and this site is not repeating them yet. The counts reported for the first day are consistent across the sources we checked. The counts reported for the second day are not: two of them disagree with each other on both the number of votes and whether an abstention was recorded. Our sourcing rule says that a figure we cannot check does not go on a page, so the tallies will appear here when FDA posts minutes or a transcript, and not before. The outcome, which every source agrees on, is stated above.
What changed in law: nothing
A recommendation from the Pharmacy Compounding Advisory Committee is advice to FDA. It is not a rule, it is not a finding, and FDA is free to disagree with it. Adding a substance to the 503A Bulks List happens by notice and comment rulemaking, which FDA has not started for any of these seven.
The practical position, as Holland & Knight put it on 4 August 2026, is that these peptides remain unlawful to compound, and FDA can continue to take enforcement action against pharmacies that compound them. Publicly available commentary from the firms following this docket suggests the rulemaking, if the agency pursues it, would run into 2027 or later.
Nothing about the vote changes the position of any product sold outside the pharmacy system either. A compounding list governs what a licensed pharmacist may compound on a prescription. It has no bearing on material sold direct to the public.
Every nomination had already been withdrawn
The detail that has gone almost unreported sits in the footnotes of FDA's briefing document. Each of the seven peptides reached the committee on a nomination, and every one of those nominations had been withdrawn by the party that filed it before the meeting took place.
The nominators named in the document are LDT Health Solutions, Inc., filing on behalf of the International Peptide Society, and Wells Pharmacy Network. The withdrawals are recorded against docket entries FDA-2015-N-3534-0484, 0485 and 0487. Against each one FDA states that it is electing to proceed with the presentation anyway.
That is worth understanding correctly, because it cuts against the reading that the meeting was industry driving an outcome. FDA convened a public evaluation of seven substances that nobody was any longer asking it to evaluate, and then recommended against all of them.
What FDA's evaluation said, substance by substance
These are FDA's findings as presented to the committee, not this site's assessment. Where the agency describes an absence of evidence, that is a statement about the record available to it in July 2026, and an absence of evidence is not a finding of harm or of benefit in either direction.
| Substance | Nominated use | What FDA concluded on effectiveness | Adverse event reports found |
|---|---|---|---|
| BPC-157 | Healing of injuries and wounds, gastrointestinal uses | Insufficient evidence to reach a conclusion. Clinical studies exist, in small numbers of subjects, by routes including rectal, intra-articular, intravesical and intravenous, with limited safety data reported | Three in FAERS, all confounded by other factors |
| KPV | Wound healing, inflammatory conditions | A lack of evidence to evaluate effectiveness. FDA identified no data on the use of KPV in humans at all | None |
| TB-500 | Healing and recovery | A lack of evidence to evaluate effectiveness | None |
| MOTS-c | Metabolic uses | A lack of evidence to evaluate effectiveness | None |
| Emideltide | Sleep | Insufficient evidence to reach a conclusion. FDA describes the available work as preliminary | None |
| Epitalon | Insomnia | A lack of evidence to support effectiveness for the nominated use. Available clinical information concerns melatonin metabolite levels rather than the nominated condition | None |
| Semax | Neurological uses | Insufficient evidence of effectiveness to support the nominated use | None |
FDA attaches the same caution to every one of the empty cells in the last column, and so do we: a lack of adverse event reports does not imply that a substance is safe or lacks toxicity. Reporting to FAERS is voluntary, the agency does not receive every report, and compounded products are reported less consistently than approved ones.
The KPV row is the one worth reading twice, because it is the compound this site has reviewed in full. FDA states that the molecular targets of KPV are unknown, and that it does not appear to interact with the melanocortin receptors that mediate the effects of the parent hormone it is a fragment of. It also cites an in vitro study in human cadaver skin finding that KPV does not permeate skin well, and notes that low permeability limits systemic exposure and the prospects of a topical preparation at the same time. Our KPV review reached the same reading of the receptor question from the published literature, independently and before these documents were read.
FDA's naming problem is the same one readers have
The meeting opened, before any substance was discussed, with an FDA presentation on conflated bulk substances and common name challenges. Its argument recurs in the evaluation of every peptide that followed.
The agency's position is that BPC-157, KPV, TB-500 and MOTS-c are common names rather than names assigned through the United States Adopted Names Council, the International Nonproprietary Name system, or IUPAC nomenclature. FDA states that it has encountered multiple salts and derivatives, including different active moieties, marketed under each of those same common names, and that inconsistent naming can leave a substance not well characterized and can carry a safety risk of its own.
That is a regulator describing the problem this site built its disambiguation pages to answer. One name in a search box can refer to more than one molecule, and which one it refers to changes what the evidence behind it is worth.
What would have to happen next
- FDA decides whether to accept the committee's advice on each substance. It is not obliged to.
- If it accepts, the agency proposes a rule and opens it for public comment.
- After comments, a final rule adds the substance to the 503A Bulks List, or does not.
- Only at that point may a compounding pharmacy use the substance under section 503A.
Until step four, the legal position of every one of these seven peptides is unchanged, including the six the committee recommended. This page carries the date it was last reviewed at the top, and it will be updated as the docket moves. Corrections go in the corrections log.
The documents
Everything above that is attributed to FDA comes from the meeting materials the agency published for the 23 and 24 July 2026 Pharmacy Compounding Advisory Committee meeting, under docket FDA-2025-N-6895. The meeting was noticed in the Federal Register on 16 April 2026 as document 2026-07361.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23 and 24 July 2026. Carries the evaluation criteria, the nominations and their withdrawals, and the fourteen Points to Consider.
- Meeting agenda. Session order, presenters, and the placement of each discussion and vote.
- FDA introductory remarks and presentations, 23 July 2026. The per substance evaluations for BPC-157, KPV, TB-500 and MOTS-c.
- FDA introductory remarks and presentations, 24 July 2026. The per substance evaluations for emideltide, epitalon and semax.
- Draft meeting roster. Committee membership and the designated federal officer.
The outcome of the votes is attributed above to the law firm and trade publications named in that section, because FDA has published no vote record. When it does, this page will carry the tallies and this paragraph will go.